MHRA

CAR-T therapy
#Aleta Biotherapeutics #Biologics #Cancer research #Cancer Research UK #CAR-T #MHRA #Oncology

Biologic CAR-T cell engager approved for UK clinical trial

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Aleta Biotherapeutics a clinical trial authorisation (CTA) to evaluate biologic ALETA-001 in a Phase I/II clinical trial in patients with B-cell malignancies who are relapsed/refractory to CD19 CAR-T cell therapy. The company’s collaboration partner, Cancer Research UK’s Centre for… Read More

#Cancer Research #News #Regulatory

Vaccine
#Covid booster #Covid-19 #HIPRA Human Health #Immunology / Virology & Vaccines #MHRA

Bimervax Covid-19 vaccine authorised in UK

Bimervax from HIPRA Human Health has been authorised in the UK after meeting the Medicines & Healthcare products Regulatory Agency’s (MHRA) required safety, quality and effectiveness standards. It becomes the ninth Covid-19 vaccine to be authorised by the UK’s independent medicines regulator. Bimervax combines… Read More

#News

#Brexit #European Commission #European Medicines Agency #MHRA #Regulatory #UK #UK budget

Two part commentary on Brexit and drug discovery

On 31 January 2020, the United Kingdom (UK) withdrew from the European Union (EU). Alongside a number of repercussions, the most impactful to the drug discovery sector arguably relates to regulatory affairs on account of adjusting from the European Medicines Agency (EMA) to the Medicines and Healthcare products Regulatory… Read More

#News

#Brexit #European Commission #European Medicines Agency #MHRA #Regulatory #UK #UK budget

Part 1: What impact has Brexit had on UK drug discovery?

On 31 January 2020, the United Kingdom (UK) withdrew from the European Union (EU). Alongside a number of repercussions, the most impactful to the drug discovery sector arguably relates to regulatory affairs on account of adjusting from the European Medicines Agency (EMA) to the Medicines and Healthcare products Regulatory Agency… Read More

#Exclusive Content #Regulatory

#Brexit #European Commission #European Medicines Agency #MHRA #Regulatory #UK #UK bidget

Part 2: What impact has Brexit had on UK drug discovery?

On 31 January 2020, the United Kingdom (UK) withdrew from the European Union (EU). Alongside a number of repercussions, the most impactful to the drug discovery sector arguably relates to regulatory affairs on account of adjusting from the European Medicines Agency (EMA) to the Medicines and Healthcare products Regulatory Agency… Read More

#Exclusive Content #Regulatory

Doctor writing a prescription
#Drug repurposing #EMA #FDA #MHRA #Regulatory #Unlicensed drug

Unlicensed and off-label drugs: What do we know?

Following the death of a cancer patient after they were given an unlicensed drug, Diana Spencer unpacks the practice of prescribing unlicensed and off-label medicines. This month, a cancer patient died and three others were hospitalised in the UK after they were administered an unlicensed version of the chemotherapy drug… Read More

#Exclusive Content #Regulatory

Patients receiving chemotherapy
#Adverse event #Cancer treatment #Chemotherapy #MHRA #NHS #Unlicensed drug

Patient dies after receiving unlicensed drug

A cancer patient died and three others were hospitalised in the UK after they were administered an unlicensed version of chemotherapy cabazitaxel. According to The Guardian, which reported on the incident, the problem was caused by an issue at private healthcare company Sciensus’… Read More

#News #Trending News

Crohn's disease
#Eli Lilly #Gastroenterology #MHRA #Phase III trial #Regulatory

Eli Lilly’s ulcerative colitis drug approved in Great Britain

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Eli Lilly’s mirikizumab for moderately to severely active ulcerative colitis. The drug is approved in adult patients who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a… Read More

#News #Regulatory

#Alzheimer's #Antibody #Eisai #MHRA #Neurodegenerative disorders #Phase II trial

Eisai applies for MHRA approval for lecanemab in Alzheimer’s

Eisai has submitted a marketing authorisation application (MAA) for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody to the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. The MAA is for the treatment of early Alzheimer’s disease (AD) (mild cognitive impairment due to AD and mild AD dementia)… Read More

#News #Regulatory

Haematology
#Cell and gene therapy #CSL #Gene therapy #Haemophilia #MHRA #Phase III trial

First gene therapy for haemophilia B approved in Great Britain

CSL’s Hemgenix (etranacogene dezaparvovec) has been authorised as the first gene therapy for adults with severe and moderately severe haemophilia B (congenital Factor IX (FIX) deficiency) in Great Britain. It has been granted a marketing authorisation for patients without a history of FIX inhibitors by the UK Medicines and Healthcare… Read More

#News #Regulatory

#Biotechnology #Cancer research #Clinical research #Innovation passport #MHRA #Solid tumours #T-Cells

Uveal melanoma drug granted MHRA Innovation Passport 

iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, has been awarded the innovative medicine designation, the Innovation Passport, for roginolisib, for the treatment of metastatic uveal melanoma by the Medicines & Healthcare products Regulatory Agency (MHRA).  Roginolisib is a first-in-class, non-ATP-competitive,… Read More

#News

Clinical trial
#ABPI #Clinical trial design #Clinical trials #MHRA #UK

Biggest overhaul of UK clinical trial regulation for 20 years

A series of new measures will be introduced by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to make it faster and easier to gain approval and run clinical trials in the UK. These changes represent the biggest overhaul in UK clinical trials regulation in… Read More

#News

Chancellor Jeremy Hunt and the Spring Budget
#Association of the British Pharmaceutical Industry #BioIndustry Association #Investment #Life sciences #MHRA #Regulatory #UK #UK budget #UK government

UK Spring Budget a ‘vote of confidence’ in UK life sciences

There was some good news for the UK life sciences sector in the government’s Spring Budget, but did it go far enough? DDW’s Diana Spencer takes a look at the industry’s reaction. There wasn’t much to write home about in the UK government’s Spring Budget, described by Bloomberg UK’s Marcus… Read More

#Business & Investment #Exclusive Content

Stamp of approval
#AstraZeneca #Cancer #Chemotherapy #Clinical research #MHRA #Oncology

First-line AZ treatment for adults with biliary tract cancer approved 

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to AstraZeneca for Imfinzi (durvalumab) in combination with gemcitabine and cisplatin in Great Britain for use as a first-line treatment of adults with locally advanced, unresectable or metastatic biliary tract cancer (BTC).1 This authorisation by… Read More

#Cancer Research #News

Mosquito
#Immunology / Virology & Vaccines #MHRA #Phase III trial #Takeda #Vaccine candidate

UK approval for dengue virus vaccine candidate

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Takeda’s vaccine candidate Qdenga for active immunisation against dengue infection from four years of age.  Dengue is the fastest spreading mosquito-borne virus and was recognised by the World Health Organization (WHO) in 2019… Read More

#News

MHRA
#AstraZeneca #Cardiovascular disease #Heart disease #MHRA

UK licence extension approved for AstraZeneca’s dapagliflozin

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted a licence extension for dapagliflozin for the treatment of symptomatic chronic heart failure (HF).  The drug is approved in patients with HF and a left ventricular ejection fraction (LVEF) >40%, including HF with mildly reduced ejection fraction (HFmrEF) and… Read More

#News #Regulatory